

MONDAY, SEPTEMBER 28, 2015Index
Number**8:00 - 8:30****Hall A****OPENING CEREMONY**

Chairperson: K. G. Alberti (United Kingdom)	354
R. Lechler (King's College London, United Kingdom)	355
D. Cummings (DSS-Co-director, USA)	356
P. Schauer (DSS-Co-director, USA)	357
L. Kaplan (DSS-Co-director, USA)	358
F. Rubino (DSS-Co-director, United Kingdom)	359
M. Hirst (President, International Diabetes Federation- IDF, United Kingdom)	360

8:30 - 9:00**Hall A****WORLD CONGRESS AND DSS: RATIONALE AND METHODS**

8:30 WORLD CONGRESS AND DIABETES SURGERY SUMMIT: INTRODUCTION F. Rubino (United Kingdom)	1
8:45 DSS-II: APPRAISAL OF EVIDENCE AND CONSENSUS DEVELOPMENT G. Taroncher-Oldenburg (USA)	2

9:00 - 10:00**Hall A****WCITT2D SESSION 1: CLINICAL TRACK - DIABETES CARE: EPIDEMIOLOGY AND LIMITATIONS OF CONVENTIONAL TREATMENTS**

Chairperson: K. G. Alberti (United Kingdom)	3
Chairperson: P. Schauer (USA)	391
9:00 EPIDEMIOLOGY OF DIABETES - STATUS OF A PANDEMIC K.G. Alberti (United Kingdom)	4
9:20 CARDIO-METABOLIC RISK IN TYPE 2 DIABETES R. Eckel (USA)	5
9:40 REDUCING CVD IN T2DM: LIMITATIONS OF CONVENTIONAL TREATMENTS D. Nathan (USA)	6

10:00 - 10:40**Hall A****WCITT2D/DSS-II: JOINT SESSION 1: CLINICAL OUTCOMES OF BARIATRIC/METABOLIC SURGERY: PART I**

Chairperson: S. Amiel (United Kingdom)	7
Chairperson: H. Lebovitz (USA)	8
10:00 DURABILITY OF DIABETES CONTROL AND REDUCTION OF MICRO- AND MACRO-VASCULAR COMPLICATIONS OF DIABETES IN THE SOS STUDY L. Carlsson (Sweden)	9
10:20 REDUCTION OF CV DISEASE AND DEATH AFTER BARIATRIC/METABOLIC SURGERY T. Adams (USA)	10

10:40 - 11:00

COFFEE BREAK, EXHIBITION AND E-POSTER VIEWING

11:00 - 12:30**Hall A****WCITT2D/DSS-II: JOINT SESSION 1: CLINICAL OUTCOMES OF BARIATRIC/METABOLIC SURGERY: PART II**

11:00	OVERVIEW OF RCTs COMPARING SURGERY VS MEDICAL THERAPY FOR T2DM P. Schauer (USA)	11
11:20	BARIATRIC/METABOLIC SURGERY VS CONVENTIONAL MEDICAL TREATMENT FOR TYPE 2 DIABETES: 5-YR FOLLOW-UP FROM AN OPEN LABEL, SINGLE CENTER, RANDOMIZED CLINICAL TRIAL S. Panunzi, G. Mingrone , A. De Gaetano, C. Guidone, A. Iaconelli, G. Nanni, M. Castagneto, S. Bornstein, F. Rubino (Italy/United Kingdom)	361
11:30	SHORT- AND LONG-TERM SAFETY OF METABOLIC/BARIATRIC SURGERY B. Wolfe (USA)	18
11:50	PANEL DISCUSSION: BENEFITS AND SAFETY OF BARIATRIC/METABOLIC SURGERY: SHORT- AND LONG-TERM Panelists:	
	R. Ratner (USA)	12
	J. Dixon (Australia)	13
	W. Herman (USA)	14
	A. Courcoulas (USA)	15
	D. Johnston (United Kingdom)	17
	R. Eckel (USA)	381

12:30 - 13:40**Hall A****WCITT2D/DSS-II: JOINT SESSION 2: CONTROVERSIAL ISSUES IN BARIATRIC/METABOLIC SURGERY**

	Chairperson: W. Cefalu (USA)	362
	Chairperson: S. Del Prato (Italy)	363
12:30	SURGERY FOR DIABETES IN PATIENTS WITH BMI < 35KG/M2 D. Cummings (USA)	20
12:50	OUTCOMES OF BARIATRIC/METABOLIC SURGERY IN ADOLESCENTS: CLINICAL EVIDENCE T.H. Inge (USA)	21
13:10	PANEL DISCUSSION: ADOLESCENTS AND THE ISSUE OF BMI Panelists:	
	J. Mechanick (USA)	23
	R.W. Grant (USA)	24
	A. Desai (United Kingdom)	25
	N. Finer (United Kingdom)	27
	M. Ford-Adams (United Kingdom)	382
	R. Eckel (USA)	383

13:40 - 14:40

LUNCH BREAK, EXHIBITION AND E-POSTER VIEWING

14:40 - 16:10**Hall A****WCITT2D SESSION 2: RESEARCH-TRACK - MECHANISMS OF ACTION OF METABOLIC SURGERY - 1**

Chairperson: D. Nathan (USA)	28
Chairperson: D. Cummings (USA)	29
14:40 WHAT DOES THE EFFECTIVENESS OF SURGERY TELL US ABOUT THE PHYSIOLOGY AND PATHOPHYSIOLOGY OF GLUCOSE HOMEOSTASIS R. Bergman (USA)	30
15:00 EFFECTS OF DIFFERENT GI PROCEDURES ON INSULIN SENSITIVITY E. Ferrannini (Italy)	31
15:20 EFFECTS OF DIFFERENT GI PROCEDURES ON BETA-CELL FUNCTION AND MASS S. Kashyap (USA)	32
15:40 PANEL DISCUSSION	
Panelists:	
G. Mingrone (Italy)	33
B. Laferrere (USA)	34
P. Jones (United Kingdom)	35
S. Persaud (United Kingdom)	36
W. Cefalu (USA)	37
S. Amiel (United Kingdom)	38

16:10 - 16:30

COFFEE BREAK, EXHIBITION AND E-POSTER VIEWING

16:30 - 18:30**Hall A****WCITT2D SESSION 3: CLINICAL TRACK - NOVEL OPERATIONS AND DEVICE-BASED INTERVENTIONS**

Chairperson: A. Barthel (Germany)	39
Chairperson: J. Morton (USA)	40
16:30 NOVEL SURGICAL PROCEDURES: DJB, IT, SADI: STATE OF THE ART R. Cohen (Brazil)	41
16:45 BALLOON/OVERVIEW AND TECHNIQUES A. Genco (Italy)	42
17:00 ENDOLUMINAL BARRIER J.W. Greve (Netherlands)	43
17:15 ENDOSCOPIC DUODENAL MUCOSAL ABLATION A.D. Cherrington (USA)	44
17:30 VAGAL STIMULATION S.A. Shikora (USA)	45
17:45 GASTRIC ELECTRIC STIMULATION H. Lebovitz (USA)	46
18:00 PANEL DISCUSSION: INTERVENTIONAL DIABETOLOGY: BETWEEN PRESENT AND FUTURE	
Panelists:	
A. Patel (United Kingdom)	47
S. Ben Haim (United Kingdom)	48
M. Galvao-Neto (Brazil)	49
L. Kaplan (USA)	50
T. Klupa (Poland)	51
J. Pinkney (United Kingdom)	52
S.A. Brethauer (USA)	53

18:30 - 20:00**Hall B****INDUSTRY ORGANIZED SYMPOSIUM: SATELLITE SYMPOSIUM – NOT INCLUDED
IN THE MAIN EVENT CME/CPD**

See pages 74-75 for further details


20:00 - 21:00**Hall C****E-POSTER SESSION (SELECTED POSTERS)**

Chairperson: B. McGowan (United Kingdom)	54
Chairperson: J. Dixon (Australia)	55
20:00 BARIATRIC SURGERY IN PATIENTS WITH TYPE 1 DIABETES A. Aminian , S. Kashyap, J. Kirwan, B. Burguera, P. Schauer, S. Brethauer (USA)	56
20:07 ACCELERATED PROTEIN DIGESTION AND AMINO ACID ABSORPTION AFTER ROUX-EN-Y GASTRIC BYPASS K. Bojsen-Moller , S. Jacobsen, C. Dirksen, N. Jorgensen, S. Reitelseder, J.E. Jensen, V. Kristiansen, J. Holst, G. Van Hall, S. Madsbad (Denmark)	58
20:14 INCIDENCE AND PREDICTORS OF HYPOGLYCAEMIA AFTER LAPAROSCOPIC SLEEVE GASTRECTOMY. L. Busetto , A. Belligoli, R. Serra, R. Fabris, C. Dal Pra', P. Fioretto, M. Sanna, L. Prevedello, M. Foletto, R. Vettor (Italy)	59
20:21 REACTIVE HYPOGLYCEMIA (HYPO) AFTER RYGB IN TYPE 2 DIABETES (T2DM) M. Nannipieri (Italy)	60
20:28 JNK INHIBITION RESTORES OBESITY-INDUCED ENDOTHELIAL DYSFUNCTION MIMICKING THE VASOPROTECTIVE EFFECTS OF ROUX-EN-Y GASTRIC BYPASS SURGERY E. Osto , P. Doytcheva, T. Baechler, E. Tarasco, G. Pellegrini, C. Matter, T. Lutz, T. Luscher (Switzerland)	61
20:35 IMPROVED GLUCOSE METABOLISM AFTER GASTRIC BYPASS. EVOLUTION OF THE PARADIGM D.J. Pournaras , J. Nygren, E. Hagström-Toft, P. Arner, C.W. Le Roux, A. Thorell (United Kingdom)	62
20:42 DOES ENDOSCOPIC DUODENAL-JEJUNAL EXCLUSION IMPROVE NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN PATIENTS WITH DIABESITY? G. Sen-Gupta , R.S. Bajwa, A.A. Roy, D.B. Butler, J. Ashmore, R. Jain, B. Hayee, S.A. Amiel, R.E.J. Ryder (United Kingdom)	63
20:49 DISCUSSION	

20:00 - 21:00**WELCOME RECEPTION****21:00 - 23:00****Hall A****NETWORKING DINNER**



SCIENTIFIC PROGRAM
TUESDAY, SEPTEMBER 29, 2015



**3RD WORLD CONGRESS
ON INTERVENTIONAL
THERAPIES FOR
TYPE 2 DIABETES**



**2ND DIABETES
SURGERY SUMMIT
DSS-II**



September 28-30, 2015 | London, UK

www.wcitt2d.org



TUESDAY, SEPTEMBER 29, 2015

Index
Number

08:00 - 10:35

Hall A

**WCITT2D SYMPOSIUM 1: THE GUT IN THE PHYSIOLOGY AND
PATHOPHYSIOLOGY OF METABOLIC DISEASES**

Chairperson: S. Bloom (United Kingdom)	64
Chairperson: F. Gribble (United Kingdom)	65
08:00 THE GUT AS AN ENDOCRINE ORGAN – ROLE IN THE REGULATION OF FOOD INTAKE AND BODY WEIGHT S. Bloom (United Kingdom)	66
08:20 THE GUT AS AN ENDOCRINE ORGAN – ROLE IN THE REGULATION OF GLUCOSE HOMEOSTASIS D. Drucker (Canada)	67
08:40 BILE ACIDS AND METABOLIC REGULATION C. le Roux (Ireland)	68
09:00 INTESTINAL NUTRIENT SENSING AND ENDOLUMINAL LEPTIN SIGNALING T. Lam (Canada)	69
09:20 GUT MICROBIOTA AND INFLAMMATION K. Clement (France)	70
09:40 THE ANTI-INCRETIN THEORY: THE ROLE OF THE GUT IN THE PHYSIOLOGY AND PATHOPHYSIOLOGY OF GLUCOSE HOMEOSTASIS F. Rubino (United Kingdom)	71
10:00 PANEL DISCUSSION: THE GUT IN OBESITY AND DIABETES	
Panelists:	
D. Nathan (USA)	72
R. Batterham (United Kingdom)	73
E. Ferrannini (Italy)	74
R. Bergman (USA)	75
R. Seeley (USA)	76
M. Peakman (United Kingdom)	77

10:35 - 10:50

COFFEE BREAK, EXHIBITION AND E-POSTER VIEWING

10:50 - 13:10**Hall A****WCITT2D SESSION 4: RESEARCH TRACK - MECHANISMS OF ACTION OF METABOLIC SURGERY – 2**

Chairperson: E. Ferrannini (Italy)	78
Chairperson: R. Bergman (USA)	79
10:50 THE PHYSIOLOGY OF METABOLIC SURGERY L. Kaplan (USA)	80
11:10 DISTRIBUTION AND REGULATION OF ENTERO-ENDOCRINE CELLS F. Gribble (United Kingdom)	81
11:30 EFFECTS OF GI SURGERY ON GUT HORMONES J.J. Holst (Denmark)	82
11:50 EFFECTS OF GI SURGERY ON BILE ACIDS AND MICROBIOTA R. Seeley (USA)	83
12:10 EFFECTS OF GI SURGERY ON INTESTINAL GLUCOSE METABOLISM AND ABSORPTION N. Stylopoulos (USA)	84
12:30 POSTPRANDIAL HYPOGLYCEMIA AFTER GASTIC BYPASS SURGERY: MECHANISTIC IMPLICATIONS AND POSSIBLE TREATMENT M.E. Patti (USA)	85
12:50 PANEL DISCUSSION: MECHANISMS OF METABOLIC SURGERY	
Panelists:	
D. Drucker (Canada)	86
J. Korner (USA)	88
J. Vidal (Spain)	89
T. Lam (Canada)	90

13:15 - 14:15**Hall B****INDUSTRY SPONSORED SYMPOSIUM: SATELLITE SYMPOSIUM – NOT INCLUDED IN THE MAIN EVENT CME/CPD**

See pages 74-75 for further details

13:15 - 14:15

LUNCH BREAK, EXHIBITION AND E-POSTER VIEWING

14:15 - 15:30**Hall A****WCITT2D SESSION 5: CLINICAL TRACK - ETHNIC CONSIDERATIONS AND REGIONAL CHALLENGES FOR METABOLIC/DIABETES SURGERY**

Chairperson: D. Hopkins (USA)	101
Chairperson: P. Chowbey (India)	102
14:15 THE CHARACTERISTICS OF DIABETES IN EAST ASIAN POPULATIONS L. Ji (China)	103
14:30 THE CHARACTERISTICS OF DIABETES IN SOUTH ASIAN POPULATIONS S. Sadikot (India)	104
14:45 DIABETES IN THE MIDDLE EAST N. Albache (Syria)	105
15:00 DIABETES AMONG BLACK AFRICANS AND CARIBBEANS S. Amiel (UK)	369
15:15 METABOLIC SURGERY IN ASIA AND MIDDLE EAST W. Lee (Taiwan)	106

15:30 - 17:00**Hall B****INDUSTRY SPONSORED SYMPOSIUM: SATELLITE SYMPOSIUM – NOT INCLUDED IN THE MAIN EVENT CME/CPD**

See pages 74-75 for further details

17:00 - 17:15

COFFEE BREAK, EXHIBITION AND E-POSTER VIEWING

17:15 - 19:45

Hall A

BREAKOUT SESSION: CLINICAL OUTCOMES OF METABOLIC/DIABETES SURGERY

Chairperson: C. le Roux (Ireland)	112
Chairperson: S. Aylwin (United Kingdom)	113
17:15 A NATIONAL REGISTRY OF BARIATRIC/METABOLIC SURGERY: THE UK EXPERIENCE R. Welbourn (United Kingdom)	114
17:30 SLEEVE GASTRECTOMY M. Gagner (Canada)	115
17:45 RYGB K. Higa (USA)	116
18:00 BPD AND DUODENAL SWITCH J. Himpens (Belgium)	117
DEBATE: SLEEVE GASTRECTOMY VS GASTRIC BYPASS FOR THE TREATMENT OF DIABETES	
18:15 THE CASE FOR SLEEVE GASTRECTOMY A.M. Lacy (Spain)	118
18:30 THE CASE FOR GASTRIC BYPASS W. Pories (USA)	119
18:45 VASOPROTECTIVE PROPERTIES OF HDL IMPROVE EARLY AFTER ROUX-EN-Y GASTRIC BYPASS BUT NOT AFTER DIET TREATMENT: THE SUPERIOR CARDIOMETABOLIC BENEFITS OF RYGB E. Osto , E. McLoughlin, P. Doytcheva, J. Manz, M. Charakida, N. Finer, L. Van Gaal, J. Deanfield, T. Lüscher (Switzerland)	121
18:57 SAFETY PROFILE AND HEALTHCARE USAGE OF BARIATRIC-METABOLIC SURGERY COMPARED TO COMMONLY PERFORMED ELECTIVE PROCEDURES D. Tassinari, S. Panagiotopoulos , E. Giorgakis, L. Castagneto-Gissey, J. Casella Mariolo, A. Salerno, A. Chang, A. Patel, A. Haq, S. Ramar, G. Galata, K.M. Schulte, F. Rubino (United Kingdom)	122
19:09 PANEL DISCUSSION: CHOOSING THE APPROPRIATE PROCEDURE FOR DIABETES SURGERY	
Panelists:	
G. Rayman (United Kingdom)	123
W. Lee (Taiwan)	124
C. Boza (Chile)	125
T. Klupa (Poland)	126
A. Scheen (Belgium)	127
A. Torres (Spain)	128
A. Chang (United Kingdom)	129
J. Vidal (Spain)	130

17:15 - 19:45

Hall B

BREAKOUT SESSION: THE SCIENCE BEHIND METABOLIC SURGERY - THE MECHANISMS OF ACTION OF METABOLIC SURGERY

Chairperson: R. Batterham (United Kingdom)	132
Chairperson: J. Kirwan (USA)	133
17:15 POTENTIATION OF THE INCRETIN EFFECT BY GI SURGERY B. Laferrere (USA)	134
17:30 GASTROINTESTINAL BYPASS REDUCES PHYSIOLOGIC ANTI-INCRETIN MECHANISMS G. Mingrone (Italy)	135
17:45 GI SURGERY: EFFECTS ON GLUCOSE ABSORPTION F. Pattou (France)	136
18:00 DO THE EFFECTS OF VERY LOW CALORIE DIET MIMIC THOSE OF RYGB? J. Korner (USA)	137
18:15 ROLE OF THE DUODENUM IN THE ANTI-DIABETIC EFFECTS OF RYGB D. Cummings (USA)	138
18:30 GASTRIC BYPASS SURGERY: ALTERED ENTEROINSULAR AXIS M. Salehi (USA)	139
18:45 ATTENUATION OF DIABETIC KIDNEY DISEASE IN THE ZUCKER DIABETIC FATTY RAT FOLLOWING ROUX EN Y GASTRIC BYPASS N. Docherty , K. Neff , J. Elliott , S. Jackson , D. Higgins , C. Corteville , T. Lutz , M. Bueter , C. Godson , C. Le Roux (Ireland)	140
18:57 PET-CT SCANNING REVEALS INCREASED INTESTINAL GLUCOSE UPTAKE IN PATIENTS WITH PRIOR GASTRIC SURGERY E. Franquet, G.M. Kolodny, A. Goldfine, M.E. Patti (USA)	141
19:09 DIFFERENCES IN REGIONAL BRAIN RESPONSES TO FOOD INGESTION AFTER ROUX-EN-Y GASTRIC BYPASS (RYGB) AND THE ROLE OF GUT-PEPTIDES: A NEUROIMAGING STUDY K. Hunt , J. Dunn, P. Marsden, C. Le Roux, A. Patel, A. Pernet, B. Wilson, S. Amiel (United Kingdom)	142
19:21 PANEL DISCUSSION: WEIGHT-DEPENDENT EFFECTS OR CHANGES IN GASTROINTESTINAL PHYSIOLOGY: CAN THE ARGUMENT BE SETTLED?	
Panelists:	
R. Bergman (USA)	143
J.J. Holst (Denmark)	144
F. Gribble (United Kingdom)	146
G. Frühbeck (Spain)	384

17:15 - 19:45**Hall C****BREAKOUT SESSION: DIABETES SURGERY POLICY LAB - COST EFFECTIVENESS, COVERAGE AND ACCESS TO CARE. (CLOSED SESSION - BY INVITATION ONLY)**

Chairperson: W. Herman (USA)	147
17:15 CLINICAL OUTCOMES OF BARIATRIC SURGERY: WHAT POLICY MAKERS SHOULD KNOW P. Schauer (USA)	370
17:30 COVERAGE OF BARIATRIC/METABOLIC SURGERY: REGIONAL DIFFERENCES J. Dixon (Australia)	151
17:45 CLOSING THE TREATMENT GAP: BENEFITS AND COSTS OF MORE ACCESS TO BARIATRIC SURGERY J. Sussex, A. Martin (RAND Europe, UK)	372
18:15: POLICY LAB Lead Facilitator: R. Pow (UK)	373
<p>The Policy Lab will bring together senior clinicians, academics and health policy figures to debate policy responses to the emerging global challenge of type 2 diabetes, specifically the role of bariatric/metabolic surgery as a treatment for specific population groups. The workshop seeks to navigate the current evidence on clinical outcomes and cost-effectiveness of surgical treatment of type 2 diabetes and debate whether benefits to patients and health services could be realised by expanding access to it. The overarching aim of this session is to identify and address barriers that may prevent access to care when indicated. The Policy Lab is hosted by the Policy Institute at King's College London in partnership with RAND Europe.</p>	

19:45 - 20:45**Hall B****INDUSTRY SPONSORED SYMPOSIUM: SATELLITE SYMPOSIUM - NOT INCLUDED IN THE MAIN EVENT CME/CPD**

See pages 74-75 for further details

19:45 - 21:15

Hall A

SYMPOSIUM: LATIN AMERICAN SYMPOSIUM- METABOLIC SURGERY: SCIENCE AND PATIENT CARE. HOSTED BY THE BRAZILIAN SOCIETY OF BARIATRIC AND METABOLIC SURGERY

WELCOME AND INTRODUCTION	158
R. Cohen (Brazil)	
19:45 WHAT ARE THE CURRENT LIMITS FOR THE MEDICAL TREATMENT OF T2DM?	159
C. le Roux (Ireland)	
T2DM IMPROVEMENT AFTER METABOLIC SURGERY	160
Moderator: A. Ramos (Brazil)	
19:52 IT'S ALL ABOUT INCRETINS	161
J.J. Holst (Denmark)	
19:59 THERE IS MORE THAN INTESTINAL HORMONES	162
R. Seeley (USA)	
OUTCOMES	163
Moderator: P. Omelanczuk (Argentina)	
20:06 WHY SG IS MY ONLY CHOICE FOR DIABETES SURGERY	164
A.M. Lacy (Spain)	
20:13 ARE THE SG METABOLIC EFFECTS DURABLE? 5 YEARS EXPERIENCE	165
C. Boza (Chile)	
20:20 METABOLIC EFFECTS OF RYGBX SG: BOLD DATABASE CONCLUSIONS	166
J. Morton (USA)	
20:27 EFFECTS OF METABOLIC/BARIATRIC SURGERY OVER MORTALITY	167
T. Adams (USA)	
NEW PERSPECTIVES	168
Moderator: M. Herrera (Mexico)	
20:34 ENDOSCOPIC APPROACH	169
M. Galvao-Neto (Brazil)	
20:41 HYPERTENSION IMPROVEMENT & METABOLIC SURGERY	170
C. Schiavon (Brazil)	
GUIDELINES	171
Moderator: O. Brasesco (Argentina)	
20:48 NEW GUIDELINES FOR METABOLIC SURGERY IN LATIN AMERICA: FINALLY MOVING FORWARD?	172
S. Fuentes (Argentina)	
20:55 THE BRAZILIAN METABOLIC SCORE	173
J. Martins Campos (Brazil)	
21:02 COMMENTS	174
L. Turrati (Brazil)	

19:45 - 20:15


Hall C

**INDUSTRY SPONSORED SYMPOSIUM: SATELLITE SYMPOSIUM – NOT INCLUDED
IN THE MAIN EVENT CME/CPD**

See pages 74-75 for further details



SCIENTIFIC PROGRAM
WEDNESDAY, SEPTEMBER 30, 2015



**3RD WORLD CONGRESS
ON INTERVENTIONAL
THERAPIES FOR
TYPE 2 DIABETES**



**2ND DIABETES
SURGERY SUMMIT
DSS-II**



September 28-30, 2015 | London, UK

www.wcitt2d.org



WEDNESDAY, SEPTEMBER 30, 2015Index
Number**8:00 - 10:00****Hall A****WCITT2D/DSS-II: JOINT SESSION 4 - DIABETES SURGERY: INDICATIONS AND MODEL OF CARE - PRESENTATION OF RECOMMENDATIONS AND GUIDELINES FOR DIABETES SURGERY**

Chairperson: R. Eckel (USA)	176
Chairperson: S. Amiel (United Kingdom)	177
8:00 DEFINITION OF DIABETES-SPECIFIC GOALS AND SUCCESS OF SURGICAL TREATMENT R. Ratner (USA)	178
8:15 PREOPERATIVE WORK-UP IN DIABETES SURGERY D. Johnston (United Kingdom)	179
8:30 POSTOPERATIVE FOLLOW-UP IN DIABETES SURGERY J. Mechanick (USA)	180
8:45 INTEGRATING MEDICAL AND SURGICAL THERAPIES TO OPTIMIZE OUTCOMES S. Del Prato (Italy)	181
9:00 DSS-II: INDICATIONS TO DIABETES SURGERY AND NEW ALGORITHM FOR DIABETES MANAGEMENT K. G. Alberti (United Kingdom)	182
9:15 PANEL DISCUSSION AND VOTING SESSIONS WITH EXPERTS AND AUDIENCE:	
Panelists:	
D. Nathan (USA)	183
R.W. Grant (USA)	184
W. Herman (USA)	185
J. Morton (USA)	186
J. Pinkney (United Kingdom)	187
P. Schauer (USA)	188
W. Cefalu (USA)	189
H. Lebovitz (USA)	191

10:00 - 10:20

COFFEE BREAK, EXHIBITION AND E-POSTER VIEWING

10:20 - 12:40

Hall A

WCITT2D - SESSION 6: POLICY TRACK - COST-EFFECTIVENESS OF DIABETES SURGERY AND HEALTH CARE POLICIES

Chairperson: B. Wolfe (USA)	192
Chairperson: K. G. Alberti (United Kingdom)	193
10:20 THE COST OF DIABETES W. Herman (USA)	194
10:35 SUMMARY OF EVIDENCE FOR DIABETES SURGERY L. Kaplan (USA)	195
10:50 NICE GUIDELINES R. Batterham (United Kingdom)	197
11:05 CLOSING THE TREATMENT GAP: BENEFITS AND COSTS OF MORE ACCESS TO BARIATRIC/ METABOLIC SURGERY A. Martin (United Kingdom)	375
11:20 RESULTS OF THE "DIABETES SURGERY POLICY LAB": CHALLENGES, BARRIERS AND SOLUTIONS FOR THE IMPLEMENTATION OF SURGERY AS A TREATMENT FOR TYPE 2 DIABETES J. Rubin (United Kingdom)	376
11:40 ROUND TABLE BARRIERS TO ACCESSING SURGICAL TREATMENT OF OBESITY AND DIABETES: COSTS OR STIGMA?	
R. Ratner (Chief Scientific and Medical Officer, American Diabetes Association - ADA)	378
S. Sadikot (President-Elect, International Diabetes Federation-IDF)	393
S. O'Neill (Director of Health Intelligence and Professional Liaison - Diabetes UK)	380
J. Morton (President, American Society for Metabolic and Bariatric Surgery - ASBMS)	379
T. Kelly (Head of Care for Diabetes UK)	394
W. Herman (Chair, Professional Practice Committee, American Diabetes Association - ADA)	395

12:40 - 14:00**Hall A****WCITT2D/DSS-II: JOINT SESSION 5 - CHOICE OF SURGICAL PROCEDURE**


Chairperson: H. Sugerman (USA)	200
Chairperson: W. Pories (USA)	201
12:40 RISK/BENEFIT PROFILE OF GASTRIC BANDING J. Dixon (Australia)	202
12:50 RISK/BENEFIT PROFILE OF BILIOPANCREATIC DIVERSION G. Mingrone (Italy)	203
13:00 RISK/BENEFIT PROFILE OF SLEEVE GASTRECTOMY J. Vidal (Spain)	204
13:10 RISK/BENEFIT PROFILE OF GASTRIC BYPASS R. Cohen (Brazil)	205
13:20 PRESENTATION OF DSS-II RECOMMENDATIONS / GUIDELINES: THE CHOICE OF THE SURGICAL PROCEDURE A. Courcoulas (USA)	206
13:30 PANEL DISCUSSION AND VOTING SESSION WITH EXPERTS AND AUDIENCE	
Panelists:	
A.M. Lacy (Spain)	208
S. Ikramuddin (USA)	209
B. Wolfe (USA)	210
J. Mechanick (USA)	211
J. Morton (USA)	212
A. Patel (United Kingdom)	213
M. Gagner (Canada)	214

14:00 - 14:05**Hall A****CLOSING REMARKS / ADJOURN****14:05 - 15:00**

LUNCH, EXHIBITION AND E-POSTER VIEWING

15:00 - 15:10**Hall B****GROUP PICTURES****15:10 - 17:10****Hall B****DSS-FACE-TO-FACE MEETING (ONLY FOR DSS DELEGATES)**

E-POSTERS



**3RD WORLD CONGRESS
ON INTERVENTIONAL
THERAPIES FOR
TYPE 2 DIABETES**



**2ND DIABETES
SURGERY SUMMIT
DSS-II**



September 28-30, 2015 | London, UK

www.wcitt2d.org



E-POSTERS

COST EFFECTIVENESS OF SURGERY AS A TREATMENT OF DIABETES		
P-001	DEFINING AND DETERMINING VALUE FOR OBESITY SURGERY R. Blackstone , D. Haas, R.C. Bay, J. Crandall, R.S. Kaplan (USA)	215
P-002	THE ECONOMICS OF BARIATRIC SURGERY FROM THE PERSPECTIVE OF A PRIMARY CARE PHYSICIAN R. Eliosoff (Canada)	216
P-003	EVOLUTION OF HYPERTENSION IN OBESE DM2 PATIENTS WITH GASTRIC BYPASS P. Omelanczuk , M. Sanchez, M. Berducci, N. Pampillon, M. Abaurre, A. Ojeda, V. Lasagni, R. Palma, S. Omelanczuk, C. Penutto (Argentina)	217
P-004	LIPID PANEL FOR DIABETES ONE YEAR AFTER SURGERY CONSIDERING ADA OBJECTIVES P. Omelanczuk , M. Sanchez, M. Berducci, N. Pampillon, M. Abaurre, A. Ojeda, V. Lasagni, R. Palma, S. Omelanczuk, C. Penutto (Argentina)	218
P-005	NONALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK IN MORBIDLY OBESE PATIENTS UNDERGOING BARIATRIC SURGERY P. Omelanczuk , M. Sanchez, M. Berducci, N. Pampillon, M. Abaurre, A. Ojeda, V. Lasagni, R. Palma, S. Omelanczuk, C. Penutto (Argentina)	219
P-006	EFFECT OF BARIATRIC SURGERY ON 948 CASES WITH DIABETES OR IMPAIRED FASTING GLUCOSE: AN IRANIAN COHORT STUDY A.R. Pazouki , A. Kabir, R. Riaz, M.R. Abdolhossein (Tehran)	220
P-007	HOW EVOLUTION AND COMPARED ANATOMY GIVE SUPPORT METABOLIC SURGERY? AN INTERDISCIPLINARY REVIEW S. Santoro (Brazil)	221
P-008	TRANSIT BIPARTITION: RESULTS SIMILAR TO A BPD, HOWEVER WITH MINIMAL MALABSORPTION. LONG TERM FOLLOW-UP S. Santoro , C.E. Malzoni, M.C.P. Velhote, A. Lacombe, C.G. Aquino (Brazil)	222
P-009	ONE YEAR METABOLIC OUTCOMES OF BARIATRIC SURGERY IN A MULTI-ETHNIC ASIAN OBESE DIABETIC COHORT Z. Zhiyan, C. Khoo, S.B. Jimmy, L. Davide, A. Shabbir (Singapore)	223

EFFECTS OF BARIATRIC/METABOLIC SURGERY ON DIABETES-RELATED COMPLICATIONS

- P-010 THE INFLUENCE OF DIABETES AND MAJOR DEPRESSION ON CAROTID INTIMA-MEDIA THICKNESS IN BARIATRIC SURGERY CANDIDATES 224
E. Bianciardi, G. Di Lorenzo, P. Gentileschi, C. Niolu, M. Cardellini, F. Davato, A. Siracusano, M. Federici (Italy)
- P-011 GASTRIC BYPASS IMPROVES SUBCLINICAL NEPHROPATHY IN NON-SEVERELY OBESE PATIENTS (BMI 35KG/M2) WITH TYPE 2 DIABETES MELLITUS 225
A. Billeter, S. Kopf, B. Israel, T. Schulte, P. Knefeli, M. Büchler, P. Nawroth, B. Müller (Germany)
- P-012 5-YEAR DRUG COSTS AFTER GASTRIC BYPASS IN PATIENTS WITH DIABETES 226
G. Bruze (Sweden)
- P-013 WOULD END STAGE RENAL FAILURE PATIENTS ON RENAL DIALYSIS HAVE REMISSION OF DIABETES MELLITUS AND RENAL FAILURE AFTER BARIATRIC SURGERY? 227
A. Goralczyk, U. Parampalli, M. Adebibe, J. Dattani, G.N. Zumbadze, M. Plaha, K. Devalia, K.R. Mannur (United Kingdom)
- P-014 INCREASED BUTYRYLCHOLINESTERASE ACTIVITY ARE ASSOCIATED WITH OBESITY AND DIABETES AND S100B ELEVATED IN OBESE T2DM SERUM DECREASED AFTER BARIATRIC SURGERY 228
R.M. Guaragna, F. Rohden, F. Schmidt, N. Coimbra Scaglia, A. Wyse, A. Padoin, C. Cora Mottin (Brazil)
- P-015 ROUX-EN-Y GASTRIC BYPASS STIMULATES HYPOTHALAMIC MIR-122 AND INHIBITS CARDIAC AND HEPATIC MIR-122 EXPRESSIONS 229
E. Ha (Korea)
- P-016 DUODENAL-JEJUNAL BYPASS SURGERY ATTENUATES NONALCOHOLIC FATTY LIVER DISEASE VIA DOWNREGULATION OF FATTY ACID SYNTHESIS IN MICE 230
E. Ha, T.K. Ha (Korea)
- P-017 ASSESSMENT OF DIABETIC MICROVASCULAR COMPLICATIONS 5 YEARS AFTER BARIATRIC SURGERY 231
A. Humphreys, S. Ravindra, A. Miras, L. Gerassimos, S. Allen, A. Ahmed, K. Moorthy, S. Purkayastha, T. Tan, H. Chahal (United Kingdom)
- P-018 BARIATRIC AND METABOLIC SURGERY IN INDIA: A REVIEW 232
S. Ikramuddin, S. Agarwal (USA)
- P-019 REVIEW OF COST EFFECTIVENESS STUDIES ON BARIATRIC SURGERY 233
S. Ikramuddin, S. Agarwal (USA)
- P-020 GASTRO INTESTINAL BY-PASS PATIENTS WITH DIABETIC FOOT OSTEOMYELITIS: SELECTED ANTIBIOTHERAPY AFTER RADIO GUIDED BONE BIOPSY SHOULD BE INTRAVEINOUS RATHER THAN ENTERAL 234
F. Mercier, M. Lacomme, K. Merah, K. Mohammedi, J.C. Dupre, J.C. Labbe-gentils, Jaber C. (France)

- P-021 GASTRIC BYPASS IMPROVES STEATOSIS AND STEATOHEPATITIS IN PATIENTS (BMI 35KG/M²) WITH TYPE 2 DIABETES MELLITUS 235
B. Müller, A. Billeter, B. Straub, B. Israel, T. Schulte, P. Knefeli, P. Schirmacher, M. Büchler, P. Nawroth (Germany)
- P-022 LAPAROSCOPIC SLEEVE GASTRECTOMY IMPROVES NONALCOHOLIC FATTY LIVER DISEASE IN JAPANESE DIABETES PATIENTS WITH SEVERE OBESITY 236
A. Sasaki, H. Nitta, K. Otsuka, S. Baba, A. Umemura, T. Takahara, T. Iwaya, S. Nishizuka, K. Koeda, M. Mizuno (Japan)

EPIDEMIOLOGY AND ECONOMIC IMPACT OF DIABETES

- P-024 CANDIDAL COLONIZATION, STRAIN DIVERSITY AND SALIVARY PH AMONG SUBJECTS WITH TYPE II DIABETES MELLITUS 238
A. Monea, A.C. K.-Ivacson, G. Beresescu (Romania)
- P-025 TYPE II DIABETES MELLITUS AND CARDIOVASCULAR RISK AMONG MEXICAN CHILDREN WITH OBESITY IN A ELEMENTARY SCHOOL IN MEXICO CITY 239
H. Ortiz-Perez, I. Martinez-Barbabosa , R. Cordova-Moreno , M. Aguilar-Venegas (Mexico)
- P-028 STATISTICAL STUDY EXAMINING THE RELATION BETWEEN PREVALENCE OF DIABETES AND FOOD INSECURITY IN THE UNITED STATES 242
G. Schur (USA)
- P-031 EXPLORING INEQUALITIES IN DIABETES CARE FOR OLDER SOUTH ASIAN PEOPLE IN THE UK: A REALIST REVIEW OF THE LITERATURE 245
E. Wilkinson, M. Waqar, G. Randhawa (United Kingdom)

IMPACT OF BARIATRIC/METABOLIC SURGERY ON CARDIOMETABOLIC RISK

- P-032 METABOLIC CHANGES AFTER ROUX-N-Y BARIATRIC SURGERY IN HISPANICS 246
P.I. Altieri, J. Hernández-Gil de Lamadrid, J.J. Nieves-Rivera, L. Mora, L. Corretjer, A. Suárez, H.L. Banchs, J. Muñoz, N. Escobales, M. Crespo (Puerto Rico)
- P-033 IMPROVED INSULIN SENSITIVITY, GLUCOSE TOLERANCE AND LIVER STEATOSIS IN ITALIAN SUBJECTS FROM THE FLORINASH STUDY: A 4 YEARS FOLLOW UP STUDY 247
M. Cardellini, F. Davato, I. Cardolini, M. Ballanti, D. Benavoli, R. Burcelin, J.M. Fernandez-Real, P. Gentileschi, **M. Federici** (Italy)
- P-034 DECREASED CARDIOVASCULAR RISK FACTORS (CVRF) AFTER METABOLIC SURGERY (MS) IN MORBID OBESE PATIENTS: LONG TERM FOLLOW UP (FU) (6 TO 13 YEARS) 248
S. Faria, O. Faria, L. Berber, M. Facundes, R. Cohen (Brazil)
- P-035 LONG-TERM IMPROVEMENT OF CARBOHYDRATE PARAMETERS AFTER GASTRIC BYPASS (IN CASES OF SEVERE OBESITY) 249
S. Gomez-Abril, M. Rocha, C. Morillas-Ariño, J.L. Ponce-Marco, A. Hernandez-Mijares, T. Torres-Sanchez, F. Delgado-Gomis (Spain)
- P-036 IMPACTS OF BARIATRIC SURGERY ON BEHAVIOURAL AND FREE-LIVING PHYSICAL ACTIVITY FACTORS RELATED TO REDUCTIONS IN CARDIO-METABOLIC RISK: A MIXED-METHODS STUDY 250
S. Hanley (United Kingdom)
- P-037 HIGH-SENSITIVITY C-REACTIVE PROTEIN LEVELS DO NOT PREDICT WEIGHT LOSS RESPONSE TO BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH AND RESOLUTION OF TYPE 2 DIABETES 251
A. Tchernof, M. Nadeau, L. Biertho, S. Biron, F.S. Hould, S. Marceau, M.C. Vohl (Canada)

IMPACT OF BARIATRIC/METABOLIC SURGERY ON GLYCEMIC CONTROL

- P-038 LONG TERM CLINICAL AND FUNCTIONAL IMPACT OF BILIOPANCREATIC DIVERSION ON TYPE 2 DIABETES IN NON MORBIDLY OBESE PATIENTS. 252
G. Adami, N. Scopinaro (Italy)
- P-039 THE LONG-TERM IMPACT OF BILIOPANCREATIC DIVERSION ON GLYCEMIC CONTROL IN THE SEVERELY OBESE WITH TYPE 2 DIABETES MELLITUS IN RELATION TO PRE-OPERATIVE DURATION OF DIABETES. 253
G. Adami, N. Scopinaro (Italy)
- P-039A EFFECT OF ROUX-EN-Y GASTRIC BYPASS ON PREDIABETES AND DIABETES IN SEVERELY OBESE ADOLESCENTS IN SWEDEN AND THE USA
A.J. Beamish, T. Olbers, E. Gronowitz, T. Jenkins, J. Dahlgren, C.E. Flodmark, C. Marcus, T.H. Inge (Sweden)
- P-040 PRELIMINARY RESULTS OF A RANDOMISED STUDY COMPARING HYPOGLYCAEMIC EPISODES AFTER GASTRIC BYPASS AND SLEEVE GASTRECTOMY 254
E. Capristo, V. Spuntarelli, L. Marini, M. Raffaelli, A. Iaconelli, C. Callari, C. Guidone, R. Bellantone, G. Mingrone (Italy)

	Index Number
P-041 EARLY EFFECTS OF RYGB AND BPD ON INSULIN SENSITIVITY AND SECRETION AND ON INCRETIN L. Castagneto-Gissey , J. Casella Mariolo , G. Mingrone , A. Iaconelli, C. Guidone, E. Capristo (United Kingdom)	255
P-042 EFFECT OF BARIATRIC SURGERY ON TYPE 1 DIABETES L. Chuah , K. Hunt, R. Bhatti, A. Patel, F. Rubino, C. Le Roux, B. McGowan (United Kingdom)	256
P-043 SHORT AND MID TERM METABOLIC EFFECTS OF ROUX-Y-GASTRIC BYPASS AND SLEEVE GASTRECTOMY IN MORBIDLY OBESE SUBJECTS WITH TYPE 2 DIABETES L. Genser , G. Baud, M. Pigeyre, H. Verkindt, R. Caiazzo, F. Pattou (France)	257
P-044 SELECTION OF BYPASS VS SLEEVE FOR THE MANAGEMENT OF TYPE-2 DIABETES: IS THERE CLEARLY A DIFFERENCE? A. G. Bhasker , J. Dixon, M. Lakdawala (India)	258
P-045 METABOLIC PATHWAYS FROM BARIATRIC SURGERY TO TYPE 2 DIABETES MELLITUS J. Graessler , V. Kamvissi, K.M. Schulte, F. Rubino, S.R. Bornstein (Germany)	259
P-046 MEDIUM-TERM EFFECT OF GASTRIC BYPASS ON INSULIN AND GLUCOSE RESPONSE IN A WEIGHT STABLE MINIPIG MODEL L. Hurtado (Spain)	260
P-047 INHIBITORY EFFECT OF BLOOD PLASMA TRIGLICERYDES IN THE TREATMENT OF TYPE 2 DIABETES WITH GASTRIC CONTRACTILITY MODULATION (GCM) J. Kozakowski , H.E. Lebovitz, A. Kiciak, W. Zgliczyński, W. Tarnowski (Poland)	261
P-048 THE EFFECT OF INTRA-GASTRIC BALLOON AND GLP-1 RECEPTOR AGONIST THERAPY ON GLUCOSE METABOLISM AND WEIGHT LOSS ACCORDING TO EATING BEHAVIOUR E. Melnikova, E. Kravchuk , A. Neimark, A. Babenko (Russia)	262
P-049 DIABETES SURGERY ABCD SCORE IS BETTER THAN DIAREM SCORE FOR PREDICTING T2DM REMISSION AFTER METABOLIC SURGERY W.J. Lee , Z. James , A. Abdullah, C. Shu-Chu, T. Jun-Juin, C. Jung-Chien, S. Kong-Han (Taiwan)	263
P-052 GLYCEMIC CONTROL IN ZUCKER DIABETIC FATTY RATS AFTER BARIATRIC SURGERY OR CALORIC RESTRICTION INDUCED WEIGHT LOSS T. Lutz (Switzerland)	266
P-053 LAPAROSCOPIC SINGLE ANASTOMOSIS SLEEVE ILEAL BYPASS (SASI BYPASS) : TECHNIQUE AND PRELIMINARY RESULTS T. Mahdi (United Arab Emirates)	267
P-054 EFFICACY OF MINI GASTRIC BYPASS IN DIABETIC PATIENTS WITH BODY MASS INDEX LESS THAN 34 KG/M2 , SHARJAH EXPERIENCE T. Mahdi (United Arab Emirates)	268
P-055 INSULIN RESISTANCE REVISITED S. Salinari, F. Rubino, A. Bertuzzi, E. Previti, C. Guidone, G. Mingrone (Italy)	269

P-056	DYNAMIC CHANGES OF INSULIN SENSITIVITY AND SECRETION AFTER SLEEVE GASTRECTOMY G. Casella, E. Soricelli, L. Castagneto-Gissey, A. Redler, N. Basso, G. Mingrone (Italy)	270
P-057	REMISSION OF TYPE-2 DIABETES IN OBESE PATIENTS: COMPARISON OF SLEEVE GASTRECTOMY WITH GASTRIC BYPASS/MINI-BYPASS M.A. Motamedi, A. Khalaj , M. Barzin (Iran)	271
P-058	THE EFFECT OF LAPAROSCOPIC SINGLE ANASTOMOSIS GASTRIC BYPASS ON TYPE 2 DIABETES MELLITUS M.M. Ozmen , T.T. Sahin, S. Isgandarova, C. Allahverdiyev, E. Guldogan (Turkey)	272
P-059	EFFECT OF WEIGHT REGAIN ON GLYCAEMIC CONTROL IN TYPE 2 DIABETIC PATIENTS SUBMITTED TO BILIOPANCREATIC DIVERSION WITH BMI BELOW 35 F.S. Papadia , G.B. Camerini, F. Carlini, N. Scopinaro (Italy)	273
P-060	ALTERATIONS IN THE PROLIFERATION OF PANCREATIC CELLS IN PATIENTS WITH SEVERE HYPOGLYCEMIA FOLLOWING ROUX-EN-Y GASTRIC BYPASS M. Patti , A. Goldfine, J. Hu, D. Hoem, A. Molven, J. Goldsmith, W. Schwesinger, F. Folli, R. Kulkarni (USA)	274
P-061	SODIUM DEPENDENT GLUCOSE INTESTINAL ABSORPTION PLAYS A CRUCIAL ROLE IN POSTPRANDIAL GLUCOSE HOMEOSTASIS AFTER ROUX-EN-Y GASTRIC BYPASS IN THE MINIPIG G. Baud , M. Daoudi, H. Thomas, V. Raverdy, P. Pigny, K. André, V. Gmyr, R. Caiazzo, F. Pattou (France)	275
P-062	BETA-CELL FUNCTION AND MASS AFTER GASTRIC BANDING, ROUX-EN-Y GASTRIC BYPASS AND VERTICAL SLEEVE GASTRECTOMY: A PROSPECTIVE CONTROLLED STUDY. G. Baud , V. Raverdy, M. Pigeyre, R. Caiazzo, F. Pattou (France)	276
P-063	PREDICTION OF EARLY DIABETES REMISSION AFTER GASTRIC BYPASS: A DIRECT STUDY J. Ried , G. Baud, V. Raverdy, J. Gassenhuber, F. Pattou (Germany)	277
P-064	ASSESSMENT OF DIABETES REMISSION 5 YEARS AFTER BARIATRIC SURGERY USING THE AMERICAN DIABETES ASSOCIATION (ADA) AND INTERNATIONAL DIABETES FEDERATION (IDF) CRITERIA S. Ravindra , A. Humphreys, A. Miras, S. Allen, A. Ahmed, K. Moorthy, S. Purkayastha, J. Cousins, T. Tan, H. Chahal (United Kingdom)	278
P-065	T2DM STATUS IN SLEEVE GASTRECTOMY PATIENTS AFTER WEIGHT REGAIN: 2 YEARS FOLLOW UP OF 452 PATIENTS D. Sargsyan , M. Bashah, M. Al Kuwari, W. Elhag, M. Rizwan, M. Karam, A. Al Naggari, N. Khidir, I. Mustafa, M. El Sherif (Qatar)	279
P-066	LONG-TERM RESULTS OF LAPAROSCOPIC SLEEVE GASTRECTOMY WITH DUODENOJEJUNAL BYPASS FOR TYPE 2 DIABETES MELLITUS Y. Seki , K. Kasama, H. Hidenori, A. Watanabe (Japan)	280

P-067	PREOPERATIVE STIMULATED C-PEPTIDE LEVELS DO NOT PREDICT IMPROVEMENT OF GLUCOSE METABOLISM IN T2DM PATIENTS AFTER GASTRIC BYPASS SURGERY	281
	E. Svehlikova , T. Pieber, A. Tuca, B. Obermayer-Pietsch, O. Freisinger, F. Tadler, B. Ernst, B. Wilms, M. Thurnheer, B. Schultes (Switzerland)	
P-068	EARLY RESULTS OF A RANDOMIZED CONTROL TRIAL OF TYPE 2 DIABETES WITH BMI 27-32 FOR RYGB VERSUS BEST MEDICAL THERAPY	282
	C.H. Tan , A. Cheng (Singapore)	
P-070	MID-TERM DIABETES REMISSION AFTER ROUX-EN-Y GASTRIC BYPASS	284
	P. Vasas , W. Al-Khyatt, S. Awad, I. Idris, P. Leeder, A. Awan, J. Ahmed (United Kingdom)	
P-071	PREDICT GLYCEMIC CONTROL AFTER METABOLIC SURGERY USING MODIFIED HOMEOSTASIS MODEL ASSESSMENT (HOMA) AND 6-MINUTES GLUCAGON STIMULATION TEST IN CHINESE OBESE TYPE 2 DIABETES PATIENTS	285
	S. Wong , S. Liu, A. Kong, C. Lam, E. Ng (Hong Kong- China)	
P-072	DUODENOJEJUNAL BYPASS SLEEVE (ENDOBARRIER) TRANSIENTLY IMPROVES DIABETIC CONTROL WHILST IN SITU - THERE IS NO HANGOVER EFFECT	286
	H. Younus , S. Chakravartty, A. Patel (United Kingdom)	

INTEGRATION OF PHARMACEUTICAL/SURGICAL THERAPIES AND OPTIMISATION OF GLCONTROL POST-SURGERY

P-073	ORAL ADMINISTRATION OF LYCIUM BARBARUM POLYSACCHARIDES (LBP) REDUCES APOPTOSIS IN BLOOD VESSELS OF DIABETIC RAT BRAINS	287
	Y. Zhang, M.C. Choi , K.K. Cheung, K.F. So, G.L.Y. Cheing (Hong Kong- China)	
P-074	PROPOSAL AND STUDY DESIGN FOR A USER LED DIET EDUCATION PROGRAMME FOR PATIENTS WITH TYPE 2 DIABETES FOLLOWING BARIATRIC SURGERY	288
	F. Gately, F. Rubino, C. Grace (United Kingdom)	
P-075	GLYCEMIC CONTROL STABILITY IN EARLY POST METABOLIC SURGERY TREATMENT FOR TYPE 2 DIABETES MELLITUS	289
	M. Moreira , J.C.D. Repka, G.C.V.F. De Souza, C.J.F. De Souza, W.P. Dos Santos, A. Nolla, D.D. Ferrarin (Brazil)	

INTESTINAL GLUCOSE METABOLISM AND NUTRIENT SENSING

- P-079 DIURNAL RHYTHMS IN THE EXPRESSION OF THE INTESTINAL SUGAR SENSORS, T1R2/3 AND SGLT3 293
C. Corpe, P. O'Brien (United Kingdom)
- P-080 XYLITOL INHIBITS-AMYLASE AND-GLUCOSIDASE ACTIVITIES, REDUCES INTESTINAL GLUCOSE ABSORPTION AND INCREASES MUSCLE GLUCOSE UPTAKE TO AMELIORATE TYPE 2 DIABETES IN RATS 294
M.S. Islam, C. Chukwuma (South Africa)
- P-081 INCREASE IN CIRCULATING BILE ACIDS IN RESPONSE TO CARBOHYDRATE AND PROTEIN MAY CONTRIBUTE TO SYMPTOMS OF DUMPING AFTER ROUX-EN-Y GASTRIC-BYPASS 295
R. Vincent, D. Taylor, A. Laurenius, T. Olbers, I. Näslund, J. Karlsson, J. Alagband-Zadeh, C. Le Roux (United Kingdom)
- P-082 INTACT NEURAL SYSTEM OF THE PORTAL VEIN IS IMPORTANT FOR MAINTAINING NORMAL GLUCOSE METABOLISM 296
H. Yamamoto, T. Yamaguchi, S. Kaida, S. Murata, M. Tani (Japan)

MECHANISMS OF ACTION OF BARIATRIC AND METABOLIC SURGERY

- P-083 MULTI-TISSUE ANALYSIS REVEALS THE METABOLIC RESPONSE OF MICE TO RYGB 9 DAYS POST-SURGERY 297
D. Ben-Zvi, N. Stylopoulos, D. Melton (USA)
- P-084 RESET OF SYNAPTIC FUNCTION IN THE BRAINSTEM *NUCLEUS TRACTI SOLITARI* THROUGH SECTION OF THE AFFERENT VAGAL FIBERS: A MECHANISM OF ACTION OF METABOLIC SURGERY 298
C. Blasi (Italy)
- P-085 RELATIONSHIP BETWEEN MUSCLE/ADIPOSE TISSUE MORPHOLOGY, INSULIN SENSITIVITY AND CELL FUNCTION IN DIABETIC AND NON-DIABETIC MORBIDLY OBESE PATIENTS: EFFECT OF BARIATRIC SURGERY 299
S. Camastra, R. Berta, A. Vitali, A. Gastaldelli, R. Bellini, S. Frascerra, B. Astiarraga, S. Cinti, M. Anselmino, E. Ferrannini (Italy)
- P-086 CHANGES IN INTESTINAL GLUCOSE HANDLING COULD EXPLAIN DIABETES RESOLUTION AFTER ROUX-EN-Y GASTRIC BYPASS 300
J.B. Cavin, A. Couvelard, R. Lebtahi, K. Arapis, E. Voitellier, L. Gillard, L. Ribeiro-Parenti, J.P. Marmuse, A. Bado, M. Le-Gall (France)
- P-087 IMPROVEMENT OF NEUROPATHY AFTER METABOLIC SURGERY: RESULTS OF AN EMG CONFIRMED PILOT STUDY 301
A. Celik, N. Uzun, A. Kayadibi, T. Adatepe, M. Ertas (Turkey)
- P-088 MEAL-INDUCED GUT AND PANCREATIC HORMONE PROFILE AFTER SLEEVE GASTRECTOMY AND GASTRIC BYPASS IN A LEAN ANIMAL MODEL OF TYPE 2 DIABETES 302
H. Eickhoff, P. Matafome, R. Seiça, F. Castro e Sousa (Portugal)

	Index Number
P-089 THE EFFECT OF BARIATRIC SURGERY ON POSTOPERATIVE GHRELIN CONCENTRATION: A SYSTEMATIC REVIEW AND META-ANALYSIS N. Geubbels , N. Lijftogt, L.M. De Brauw, M.J.M. Serlie (Netherlands)	303
P-090 INCREASED CIRCULATING MAGNESIUM CONCENTRATIONS IN TYPE 2 DIABETIC PATIENTS AFTER GASTRIC BYPASS SURGERY A. Haenni , H.E. Johansson (Sweden)	304
P-091 THE INFLUENCE OF THREE BARIATRIC PROCEDURES ON INSULIN RESISTANCE IMPROVEMENT SHOULD THE EXTENT OF UNDILUTED BILE TRANSIT BE CONSIDERED A KEY FACTOR ALTERING GLUCOSE METABOLISM? Ł. Kaska , M. Proczko, P. Wisniewski, Z. Sledzinski (Poland)	305
P-092 SLEEVE GASTRECTOMY FAILS TO IMPROVE GLUCOSE HOMEOSTASIS IN LIPOCALIN PROSTAGLANDIN D2 SYNTHASE (L-PGDS) KNOCKOUT MICE R. Lau , S. Kumar, C. Hall, T. Palaia, K. Hall, C. Brathwaite, L. Ragolia (USA)	306
P-093 ALTERATIONS IN ENERGY EXPENDITURE IN ROUX-EN-Y GASTRIC BYPASS (RYGB) RATS PERSIST AT THERMONEUTRALITY T. Lutz (Switzerland)	307
P-094 BARIATRIC SURGERY; CURE FOR TYPE 2 DIABETES S. Mahmoudi, A. Pazouki (Iran)	308
P-095 METABOLIC SIGNATURES OF ENHANCED FUEL UTILIZATION IN THE INTESTINE OF HUMAN PATIENTS AND RODENTS AFTER ROUX-EN-Y-GASTRIC BYPASS SURGERY L. Meoli , R. Muñoz, N. Stylopoulos (USA)	309
P-096 METABOLIC SURGERY - CLINICAL AND MOLECULAR IMPLICATIONS -PILOT STUDY PRELIMINARY RESULTS R. Mirica , M. Ionescu, R. Munteanu, O. Ginghina, R. Iosifescu, G. Zugravru, A. Rosca, A. Banica, N. Iordache (Romania)	310
P-097 MECHANISM OF ACTION OF SLEEVE GASTRECTOMY: DOES SIZE MATTER? D. Tassinari, J. Casella Mariolo, L. Castagneto-Gissey, E. Giorgakis, S. Panagiotopoulos, F. Rubino (United Kingdom)	311
P-098 GASTRIC BYPASS SURGERY INCREASES DUODENAL EXPRESSION OF PCSK2 IN ZUCKER DIABETIC RATS A. Alami, P.F. Pedro, N. Docherty, C. Le Roux, R. Drynda, S.L. Persaud, P.M. Jones, F. Rubino (United Kingdom)	312
P-099 GASTRIC BYPASS RATHER THAN SLEEVE GASTRECTOMY ALTERS DISTAL GUT MICROBIOTA Y. Shao , B. Xu, Q. Yao (China)	313
P-100 UNRAVELING THE EFFECTS OF ENDOGENOUS INCRETIN HORMONES ON GLUCOSE METABOLISM AFTER ROUX-EN-Y GASTRIC BYPASS SURGERY M. SVANE, K. Bojsen-Moller , N. Jorgensen, S. Nielsen, C. Dirksen, V. Kristiansen, B. Hartmann, J. Holst, S. Madsbad (Denmark)	314

P-102 METABOLIC SURGERY AMELIORATES HYPERTENSION THROUGH ANTAGONIZING SYMPATHETIC NERVE ACTIVITIES 316
H. Zhang, Y. Pu, J. Chen, W. Tong, F. Sun, Z. Lu, Q. Li, B. Wang, D. Liu, **Z. Zhu** (China)

P-103 POTENTIAL ROLE OF GASTROINTESTINAL MOTILITY UNDERLYING MECHANISMS OF IMPROVED GLYCEMIC CONTROL AFTER SLEEVE GASTRECTOMY 317
H. Yamamoto, T. Yamaguchi, S. Kaida, S. Murata, A. Furukawa, S. Ugi, H. Maegawa, M. Tani (Japan)

MISCELLANEOUS

P-104 PIG AS A REPRODUCIBLE LARGE ANIMAL MODEL FOR ASSESSMENT OF LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS EFFECTS ON METABOLIC SYNDROME 318
L. Hurtado, I. Díaz-Güemes, J.L. De la Cruz, F.M. Sánchez-Margallo (Spain)

P-105 PREOPERATIVE SERUM IRISIN LEVELS WERE ASSOCIATED WITH WEIGHT LOSS EFFECTS AFTER ROUX-EN-Y GASTRIC BYPASS 319
Y. Lee, K. Ju-hee, H. Yun-suk, C. Ji-ho, P. Sunghyoun, K. Kyung-gon (Korea)

P-106 EFFECTIVENESS OF A SOY BASED MEAL REPLACEMENT PRODUCT ON WEIGHT LOSS AND GLYCAEMIC CONTROL IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES 320
H. McCarthy, S. Koohkan, A. Berg, D. Koenig (United Kingdom)

P-109 USE OF INCRETIN RECEPTOR KNOCK-OUT CELL LINES FOR DUAL AGONISM DRUG DISCOVERY 323
J. Naylor, A. Suckow, I. Sermadiras, P. Ravn, R. Howes, J. Li, M. Snaith, D. Hornigold, M. Coghlan (United Kingdom)

P-110 PHARMACOECONOMIC EVALUATION OF ORAL ANTIDIABETICS ON DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A CLINIC OF THE SOCIAL SECURITY MEXICAN INSTITUTE IN MEXICO CITY 324
F. López-Naranjo, J. Kravzov-Jinich, R. Córdova-Moreno, **H. Ortiz-Perez**, I. Martínez-Barbabosa (Mexico)

P-111 DIET OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ITS RELATIONSHIP WITH FOOT INFECTIONS 325
I. Martínez-Barbabosa, H. Ortiz-Perez, R. Romero Cabello, R. Córdova-Moreno, M. Aguilar-Venegas (Mexico)

P-113 ADIPONECTIN: A POTENTIAL RISK FACTOR OF DIABETIC MYASTHENIA AND INTERVENTION EFFECT OF CHINESE HERB FORMULA 327
J. Zhao, M. Xie (China)

NOVEL TECHNOLOGIES AND GASTROINTESTINAL DEVICES FOR DIABETES

- P-115 DUODENAL MUCOSAL RESURFACING (DMR) AS A NEW ENDOSCOPIC TREATMENT FOR TYPE 2 DIABETES (T2DM): SAFETY AND PROOF-OF-PRINCIPLE COHORT STUDY 329
A.D. Cherrington, M.P. Galvão Neto, L. Rodriguez, P. Becerra, P. Rodriguez, P. Vignolo, H. Rajagopalan, J.D. Caplan, G. Mingrone (USA)
- P-116 DUODENO-JEJUNAL BYPASS LINER IN OBESE T2DM PATIENTS WITH ADVANCED DISEASE 330
A. García Ruiz De Gordejuela, J. Pujol Gebelli, A. Casajoana Badía, E.C. Eduard, M. Galvao Neto, N. Vilarrasa García (Spain)
- P-117 A NOVEL LAPAROSCOPIC REVERSABLE GASTRIC BAY-PASS WITH FUNDECTOMY AND ESPLORABLE STOMACH (LRYGBP FSE) 331
G. Lesti, M. Zappa, F. Altorio, A. Porta (Italy)
- P-119 GASTRIC CONTRACTILITY MODULATION: MEDIUM- TO LONG-TERM RESULTS OF A PILOT STUDY IN OBESE AND NON-OBESE TYPE 2 DIABETIC PATIENTS 333
F.S. Papadia, H. Lebovitz, G.B. Camerini, A. Belligoli, C. Flavia, N. Scopinaro (Italy)
- P-120 POSTPRANDIAL INSULIN AND INCRETIN RESPONSES AFTER GASTRIC ELECTRIC STIMULATION (DIAMOND) IN CHINESE OBESE PATIENTS WITH TYPE 2 DIABETES - A ONE YEAR FOLLOW UP 334
S. Wong, A. Kong, V. Ng, J. Holst, E. Ng, J. Chan (Hong Kong- China)
- P-121 GASTRIC CONTRACTILITY MODULATION (GCM) IN THE TREATMENT OF TYPE 2 DIABETES: A RANDOMIZED BLINDED CROSS-OVER STUDY 335
M. Zelewski, H.E. Lebovitz, B. Ludvik, J. Kozakowski, W. Tarnowski, I. Yaniv, T. Schwartz (Poland)
- P-122 OBESE TYPE 2 DIABETES PATIENTS TREATMENT WITH GASTRIC CONTRACTILITY MODULATION; NORMAL TRIGLYCERIDES PREDICT DURABLE EFFECTS FOR AT LEAST 3 YEARS 336
H.E. Lebovitz, B. Ludvik, M. Zelewski, I. Yaniv, T. Schwartz (USA)

RANDOMIZED CLINICAL TRIALS COMPARING SURGICAL PROCEDURES HEAD TO HEAD FOR THE TREATMENT OF DIABETES

- P-123 BY-BAND-SLEEVE: PRAGMATIC RCT TO EXAMINE THE EFFECTIVENESS AND COST EFFECTIVENESS OF LAPAROSCOPIC ADJUSTABLE-GASTRIC-BAND, ROUX-EN-Y-GASTRIC-BYPASS AND SLEEVE-GASTRECTOMY FOR SEVERE AND COMPLEX OBESITY 337
R. Welbourn, J. Byrne, R. Andrews, W. Caroline, J. Donovan, C. Rogers, J. Blazeby, On behalf of the By-Band-Sleeve TMG (United Kingdom)
- P-124 EFFECTS OF LAPAROSCOPIC SLEEVE GASTRECTOMY WITH OR WITHOUT ANTRUM PRESERVATION ON FOOD INTAKE: A RANDOMIZED STUDY 338
A. Molina, F. SABENCH, M. Vives, A. Bonada, S. Blanco, A. Sánchez, J. Domènech, D. Del Castillo (Spain)

ROLE OF BILE ACIDS IN GLUCOSE HOMEOSTASIS

- P-125 EFFECTS OF ORAL ADMINISTRATION OF BILE ACIDS ON GLP-1 SECRETION AFTER ROUX-EN-Y GASTRIC BYPASS 339
 S. NIELSEN, M.S. Svane, **K.N. Bojsen-Moeller**, V. Kristiansen, J.J. Holst, S. Madsbad (Denmark)
- P-126 THE RATIO OF ALPHA;-HYDROXYLATED : NON-ALPHA;-HYDROXYLATED BILE ACIDS IS NOT AFFECTED AFTER ROUX-EN-Y GASTRIC BYPASS IN HUMANS 340
R. Vincent, M. Werling, G. Cross, L. Fädriks, H. Lonroth, D. Taylor, J. Alaghband-Zadeh, T. Olbers, C. Le Roux (United Kingdom)

ROLE OF GUT MICROBIOTA IN METABOLISM AND IN THE PATHOPHYSIOLOGY OF OBESITY AND DIABETES

- P-127 AN ADIPOSE TISSUE 16S RIBOSOMAL DNA TARGETED METAGENOMIC CATALOGUE OF PATIENTS WITH METABOLIC DISEASE 341
 B. Coupé, S. Paissé, B. Lelouvier, F. Servant, A.C. Brunet, **J. Christensen**, C. Schuster-Klein, B. Guardiola-Lemaitre, F. Pattou, J. Amar, M. Courtney, R. Burcelin (France)
- P-128 GUT MICROBIOTA-DERIVED SHORT CHAIN FREE FATTY ACIDS STIMULATE INSULIN SECRETION FROM MOUSE AND HUMAN ISLETS 342
A. Pingitore, T. Hill, J. Bowe, G.C. Huang, S. Persaud (United Kingdom)
- P-129 GPCR LIGAND SECRETOME OF MOUSE DUODENUM: POSSIBLE TARGETS FOR INVESTIGATIONS ON MECHANISMS OF ACTION OF BARIATRIC/METABOLIC SURGERY 343
 P.F. Pedro, A. Alami, R. Hawkes, S. Amisten, S.J. Persaud, **F. Rubino**, P.M. Jones (United Kingdom)
- P-130 MORBID OBESITY AND RACE-RELATED HELICOBACTER PYLORI COLONIZATION 344
J. SU, C.H. Tan, A. Cheng (Singapore)

ROLE OF THE GASTROINTESTINAL TRACT IN GLUCOSE METABOLISM

- P-132 IMPAIRMENT OF INTESTINAL BARRIER INTEGRITY IN HUMAN OBESITY: INVOLVEMENT OF DIETARY LIPIDS 346
L. Genser, S. Benaissa, A. Torcivia, M. Rousset, K. Clement, E. Brot-Laroche, A. Leturque, S. Thenet, C. Poitou-Bernert (France)
- P-133 EFFICACY AND SAFETY OF SITAGLIPTIN IN SUBJECTS WITH 2 DIABETES MELLITUS WITH FATTY LIVER 347
 V. Kapetivadze, **R. Tabukashvili**, N. Gegeshidze, K. Tchaava, Z. Maglaperidze, Z. Grigorashvili (Georgia)
- P-134 CHANGE OF INTESTINAL HORMONE AFTER LAPAROSCOPIC SLEEVE GASTRECTOMY WITH DUODENAL JEJUNAL BYPASS FOR NON-MORBID OBESE T2DM PATIENTS 348
K. Kasama, Y. Seki, A. Watanabe, H. Haruta, Y. Kurokawa (Japan)

SAFETY OF BARIATRIC/METABOLIC SURGERY

- P-136 IS IT SAFE TO PERFORM BARIATRIC SURGERY IN OBESE PATIENTS WITH CHRONIC KIDNEY DISEASE? 350
D. Elfadl, S. Ramar, H. MacLaughlin, I. Macdougall, A. Patel, F. Rubino, A. Chang (United Kingdom)
- P-137 THE MANAGEMENT OF POST-PRANDIAL HYPOGLYCAEMIA (PPH)-INSIGHTS INTO THE ROLE OF GUT HORMONES IN BOTH THE PATHOLOGY AND TREATMENT OF PPH 351
G. Tharakan, P. Behary, W. Al Najim, A. Miras, S. Purkayastha, S. Hakky, K. Moorthy, A. Ahmed, H. Chahal, T. Tan (United Kingdom)
- P-138 DIAGNOSTIC LAPAROSCOPY AND REPLACEMENT OF BLOCKED CONTINUOUS INTRAPERITONEAL INSULIN INFUSION CATHETER 352
C. Tsironis, N. Penney, N. Oliver, S. Purkayastha (United Kingdom)